MX2020009348A - Composicion de glp-1 para el tratamiento de la obesidad y el control del peso. - Google Patents
Composicion de glp-1 para el tratamiento de la obesidad y el control del peso.Info
- Publication number
- MX2020009348A MX2020009348A MX2020009348A MX2020009348A MX2020009348A MX 2020009348 A MX2020009348 A MX 2020009348A MX 2020009348 A MX2020009348 A MX 2020009348A MX 2020009348 A MX2020009348 A MX 2020009348A MX 2020009348 A MX2020009348 A MX 2020009348A
- Authority
- MX
- Mexico
- Prior art keywords
- glp
- treating obesity
- composition
- weight management
- peptide
- Prior art date
Links
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title abstract 2
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title abstract 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 2
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- 230000037221 weight management Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 101000788682 Homo sapiens GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 235000020825 overweight Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Child & Adolescent Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Usos de un péptido GLP-1 humano recombinante, los usos incluyen prevenir o tratar la obesidad y/o el sobrepeso y controlar el peso corporal. La cantidad terapéuticamente eficaz del péptido GLP-1 es de aproximadamente 0.11 mg/día a aproximadamente 0.66 mg/día.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810198521.0A CN110237239A (zh) | 2018-03-09 | 2018-03-09 | 用于治疗肥胖和体重管理的glp-1组合物 |
| PCT/CN2019/077541 WO2019170153A1 (en) | 2018-03-09 | 2019-03-08 | GLP-1 Composition for Treating Obesity and Weight Management |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020009348A true MX2020009348A (es) | 2020-10-08 |
Family
ID=67846919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009348A MX2020009348A (es) | 2018-03-09 | 2019-03-08 | Composicion de glp-1 para el tratamiento de la obesidad y el control del peso. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210052703A1 (es) |
| EP (1) | EP3762017B1 (es) |
| JP (2) | JP7451413B2 (es) |
| KR (1) | KR20200130297A (es) |
| CN (2) | CN113181346A (es) |
| AU (1) | AU2019229469B2 (es) |
| BR (1) | BR112020018362A2 (es) |
| CA (1) | CA3091729A1 (es) |
| MX (1) | MX2020009348A (es) |
| WO (1) | WO2019170153A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230317230A1 (en) * | 2019-05-02 | 2023-10-05 | Closed Loop Medicine Ltd. | Method for treating obesity |
| CN115397455A (zh) * | 2020-01-16 | 2022-11-25 | 上海仁会生物制药股份有限公司 | Glp-1给药方案 |
| WO2021142737A1 (en) * | 2020-01-16 | 2021-07-22 | Shanghai Benemae Pharmaceutical Corporation | Compositions and methods for treating non-alcoholic steatohepatitis (nash) |
| WO2025098416A1 (zh) * | 2023-11-06 | 2025-05-15 | 甘李药业股份有限公司 | 用于减肥的glp-1化合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA65549C2 (uk) * | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| DE69732572T2 (de) | 1996-11-12 | 2005-12-29 | Novo Nordisk A/S | Verwendung von glp-1 peptiden |
| KR101135244B1 (ko) * | 2007-11-29 | 2012-04-24 | 한미사이언스 주식회사 | 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물 |
| EP1758575A1 (en) * | 2004-06-11 | 2007-03-07 | Novo Nordisk A/S | Counteracting drug-induced obesity using glp-1 agonists |
| US8598314B2 (en) * | 2007-09-27 | 2013-12-03 | Amylin Pharmaceuticals, Llc | Peptide-peptidase-inhibitor conjugates and methods of making and using same |
| US20130090285A1 (en) * | 2011-06-27 | 2013-04-11 | Phasebio Pharmaceuticals, Inc. | Methods of treatment with glp-1 receptor agonists |
| CN104277103A (zh) * | 2013-07-08 | 2015-01-14 | 派格生物医药(苏州)有限公司 | 包含聚合物和生物活性分子的缀合物及其用于减肥的用途 |
| CN107462559B (zh) * | 2017-08-16 | 2020-10-13 | 中国食品药品检定研究院 | Glp-1样化合物的生物学活性的体外检定方法 |
| WO2021142733A1 (en) * | 2020-01-16 | 2021-07-22 | Shanghai Benemae Pharmaceutical Corporation | Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs |
-
2018
- 2018-03-09 CN CN202110415925.2A patent/CN113181346A/zh active Pending
- 2018-03-09 CN CN201810198521.0A patent/CN110237239A/zh active Pending
-
2019
- 2019-03-08 KR KR1020207026205A patent/KR20200130297A/ko not_active Ceased
- 2019-03-08 BR BR112020018362-8A patent/BR112020018362A2/pt unknown
- 2019-03-08 WO PCT/CN2019/077541 patent/WO2019170153A1/en not_active Ceased
- 2019-03-08 AU AU2019229469A patent/AU2019229469B2/en active Active
- 2019-03-08 CA CA3091729A patent/CA3091729A1/en active Pending
- 2019-03-08 JP JP2020547101A patent/JP7451413B2/ja active Active
- 2019-03-08 EP EP19764435.4A patent/EP3762017B1/en active Active
- 2019-03-08 MX MX2020009348A patent/MX2020009348A/es unknown
-
2020
- 2020-09-09 US US17/015,500 patent/US20210052703A1/en active Pending
-
2023
- 2023-12-22 JP JP2023216533A patent/JP2024038042A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3762017A4 (en) | 2021-10-20 |
| US20210052703A1 (en) | 2021-02-25 |
| WO2019170153A1 (en) | 2019-09-12 |
| BR112020018362A2 (pt) | 2020-12-29 |
| JP7451413B2 (ja) | 2024-03-18 |
| CN113181346A (zh) | 2021-07-30 |
| CA3091729A1 (en) | 2019-09-12 |
| RU2020131381A (ru) | 2022-04-11 |
| EP3762017B1 (en) | 2025-09-17 |
| CN110237239A (zh) | 2019-09-17 |
| KR20200130297A (ko) | 2020-11-18 |
| AU2019229469A1 (en) | 2020-08-27 |
| AU2019229469B2 (en) | 2025-05-08 |
| EP3762017A1 (en) | 2021-01-13 |
| JP2021515026A (ja) | 2021-06-17 |
| JP2024038042A (ja) | 2024-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020009348A (es) | Composicion de glp-1 para el tratamiento de la obesidad y el control del peso. | |
| PE20220938A1 (es) | Compuestos agonistas de gipr | |
| ZA201902950B (en) | Acylated glp-1/glp-2 dual agonists | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| MY204827A (en) | Semaglutide in medical therapy | |
| PH12020500338A1 (en) | Acylated oxyntomodulin peptide analog | |
| PH12021550122A1 (en) | Solubilized apyrases, methods and use | |
| ZA202106570B (en) | Neuregulin-4 compounds and methods of use | |
| PH12021551243A1 (en) | Oxyntomodulin peptide analog formulations | |
| EA202193190A1 (ru) | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов | |
| MX2025003208A (es) | Terapia combinada | |
| MX386412B (es) | Composiciòn farmacèutica inmunorreguladora contra autoinmunidad en diabetes tipo i. | |
| MX389282B (es) | Composiciones y métodos para tratar sinucleinopatías. | |
| TR201900959T4 (en) | COMPOSITIONS AND ITS MEDICAL USE. | |
| MX2020012622A (es) | Tratamientos. | |
| WO2021093134A9 (zh) | 一组蛇神经生长因子及蛇神经生长因子前体在治疗老年痴呆上的应用 | |
| MX2017008505A (es) | Composicion. | |
| WO2020074927A3 (en) | Glp-1 receptor antagonists | |
| MX2023014530A (es) | Nitroxolina para su uso en el tratamiento de neurofibroma cutaneo. | |
| SA521422315B1 (ar) | ببتيدات لعلاج مرض السكرى والاضطربات ذات الصلة والوقاية منها | |
| IL282718A (en) | Compounds for use in the treatment or prevention of pain, inflammation and/or autoimmune diseases | |
| PH12021553098A1 (en) | Treatment for synucleinopathies | |
| MA53909B1 (fr) | Compositions et méthodes de stimulation ovarienne contrôlée | |
| ZA202205158B (en) | Polypeptide having mmp2-inhibitory effect |